On 16 October 2017, Rafik Karaman, published a new study in the journal of Molecules titled “Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Year.” The article aimed to study poor pharmacokinetic profiles and resistance as they are the main two drawbacks from which currently used antiviral agents suffer, thus make them excellent targets for research, especially in the presence of viral pandemics such as HIV and hepatitis C.
The results of the study demonstrated that utilizing the ester prodrug approach a novel isopropyl ester prodrug was found to be potent HIV integrase inhibitor. Further, employing the targeted delivery prodrug zanamivir and valine ester prodrug was made and shown a sole delivery of zanamivir. Additionally, VivaGel, a dendrimer macromolecular prodrug, was found to be very efficient and is now undergoing clinical trials.
For more information about the study, please contact the main author at This email address is being protected from spambots. You need JavaScript enabled to view it. or the scientific research office at This email address is being protected from spambots. You need JavaScript enabled to view it..
